Application of remimazolam tosylate in interventional thrombectomy for patients with intracranial embolization
Objective To study the efficacy and safety of remimazolam tosylate in anesthesia for interventional thrombectomy for patients with intracranial vascular embolism.Methods Eighty patients with intracranial vascular embolism who underwent interventional thrombectomy at Liaocheng Third People's Hospital from October 2021 to March 2023 were selected for the randomized controlled trial,and were divided into a mazolam combined with dezocine group(R+D group)and a propofol combined with dezocine group(P+D group)by the random number table method,with 40 cases in each group.There were 23 males and 17 males in the R+D group;they were(61.7±7.4)years old.There were 21 males and 19 females in the P+D group;they were(61.5±7.6)years old.The efficacies,adverse reactions,renal function,inflammatory factors,and T lymphocytes were compared between the R+D group and the P+D group.The mean artery pressures(MAP),heart rates(HR),and blood oxygen saturations(SpO2)were compared between the two groups after entering the room(T0),after the completion of anesthesia induction(T1),during the maintenance of anesthesia(T2),at the beginning of the operation(T3),after the operation(T4),and when they woke up after the operation(T5).The independent-sample t test and x2 test were applied.Results The operation time,recovery time,ICU time,first feeding time,time to get out of bed,and incidences of hypotension,respiratory depression,and intraoperative body movement reaction in the R+D group were all lower than those in the P+D group[(67.8±9.2)min vs.(81.4±10.6)min,(16.9±4.5)min vs.(27.1±5.2)min,(2.6±0.9)d vs.(3.9±1.1)d,(1.3±0.5)d vs.(1.8± 0.7)d,(3.1±0.8)d vs.(4.6±1.1)d,12.5％(5/40)vs.40.0％(16/40),12.5％(4/40)vs.37.5％(15/40),and 7.5％(3/40)vs.35.0％(14/40)],with statistical differences(all P＜0.05).The MAP,HR,and SpO2 at T1,T2,T3,T4,and T5 in the R+D group were lower than those in the P+D group.After the treatment,the levels of hs-CRP,TNF-α,IL-6,S100B,and MBP in the R+D group were lower than those in the P+D group[(4.1±0.7)mg/L vs.(8.2±1.1)mg/L,(10.3±2.1)pg/L vs.(16.7±3.1)pg/L,(8.5± 1.2)pg/L vs.(11.4±1.5)pg/L,(1.1±0.3)ng/L vs.(1.6±0.5)ng/L,and(3.7±0.8)μg/L vs.(4.6±1.1)μg/L];the levels of CD3+,CD4+,CD8+,and Tau protein in the R+D group were higher than those in the P+D group[(59.7±3.2)％vs.(56.1±2.8)％,(29.5±1.9)％vs.(27.3±1.8)％,(17.2±1.5)％vs.(15.4±1.4)％,and(28.5±4.3)μg/L vs.(24.3±3.9)μg/L];there were statistical differences(all P＜0.05).Conclusion Remimazolam tosylate has the advantages of good sedation effect and high safety in anesthesia for interventional thrombectomy for patients with intracranial vascular embolization,and has little impact on the patients'inflammatory response and immune function.
万方数据
维普
